In-hospital mortality of all patients with shock was 59%.594 Patients with NSTEMI developed cardiogenic shock later than patients with STEMI, and had higher-risk clinical character- istics, more extensive CAD, and more recurrent ischemia and infarction before developing shock compared with patients with STEMI, and shock developed later in patients with NSTEMI.151 Patients with NSTEMI constituted >17% of those in the SHOCK They were also older and had more comorbidi- ties but had comparable mortality to patients with STEMI. The left circumflex coronary artery was the culprit vessel in 30% of patients with NSTEMI, suggesting the presence of true poste- Dopamine in patients with cardiogenic shock may be associated with increased mortality compared with norepi- The use of percutaneous ventricular assist devices has been hampered by the need for interventional expertise, cost, and lack of supportive evidence.597 IABP has been used for and it may facilitate intervention in patients who are hemodynamically unstable, but it did not reduce mortality or secondary endpoints in 1 RCT of 598 patients with cardiogenic shock complicating AMI.268 Newer devices with higher levels of support have provided better hemodynamic support but without improved clinical outcomes compared with IABP.599,600 See Online Data Supplement 26 for additional information on cardiogenic shock. 7.3. Diabetes Mellitus: Recommendation Class I 1. 